Table 3. Associations for urinary cotinine, arsenic, and phthalates (μg/l) with cervical cancer therapy response, adjusted for covariates using multiple linear regression models.a.
Predictors | n | β | 95% | CI | P-value |
---|---|---|---|---|---|
Cotinine | 37 | −0.001 | −0.005 | 0.003 | 0.590 |
Arsenic | 37 | 0.005 | −0.002 | 0.013 | 0.173 |
MBP | 35 | 0.0003 | −0.001 | 0.002 | 0.752 |
MBzP | 35 | −0.001 | −0.013 | 0.010 | 0.831 |
MEHP | 35 | 0.0007 | −0.006 | 0.007 | 0.817 |
MEOHP | 35 | −0.016 | −0.044 | 0.012 | 0.256 |
MEHHP | 35 | 0.0006 | −0.006 | 0.007 | 0.855 |
%MEHPb | 35 | 0.015 | 0.003 | 0.03 | 0.019 |
Notes.
Adjusted for baseline tumor size (cm), age (years), urinary creatinine (mg/l), and urinary cotinine for arsenic and phthalates (μg/l).
%MEHP = 100 × (MEHP/(MEHP + MEOHP + MEHHP)) on a molar basis.
- MBP
- mono butyl phthalate
- MBzP
- mono benzyl phthalate
- MEHP
- mono (2-ethylhexyl) phthalate
- MEOHP
- mono (2-ethyl-5-oxohexyl) phthalate
- MEHHP
- mono (2-ethyl-5-hydroxyhexyl) phthalate